about
Molecular prediction for atherogenic risks across different cell types of leukocytes.Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.Assessment of vulnerable and unstable carotid atherosclerotic plaques on endarterectomy specimens.The complementary role of microCT and histopathology in characterizing the natural history of stented arteries.Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications.(S)-[6]-Gingerol inhibits TGF-β-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells.
P2860
Q30428425-A48DFE16-CAE2-4A6E-8A15-E7B26B708345Q34548738-2AB1B844-976C-464F-B37B-4064F9F32A27Q35683158-8E92BD4E-46C8-4F72-97C2-741B881FCFA8Q36824686-9AD6FEE0-94E4-42CD-9516-816547717705Q37910218-AC54662D-9DF5-4E33-9157-49BB1BCD3F44Q38134049-B3946C3D-3B7F-4F94-BA29-49D031EB66FEQ50935191-B51488A8-F4E9-470F-882C-68B48C631523
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacotherapy of coronary atherosclerosis.
@en
Pharmacotherapy of coronary atherosclerosis.
@nl
type
label
Pharmacotherapy of coronary atherosclerosis.
@en
Pharmacotherapy of coronary atherosclerosis.
@nl
prefLabel
Pharmacotherapy of coronary atherosclerosis.
@en
Pharmacotherapy of coronary atherosclerosis.
@nl
P2093
P2860
P1476
Pharmacotherapy of coronary atherosclerosis.
@en
P2093
Aloke V Finn
Frank D Kolodgie
Marc Vorpahl
Miranda C A Kramer
Renu Virmani
P2860
P304
P356
10.1517/14656560902988494
P407
P577
2009-07-01T00:00:00Z